We're changing our website design on 27 August 2017.

Cystic fibrosis

The PBS subsidises ivacaftor for patients aged 2 years or older with cystic fibrosis.

Treatment with ivacaftor can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under section 100 of the National Health Act 1953 for patients with cystic fibrosis.

Section 100 arrangements

This item is available to a patient who is attending:

  • an approved private hospital
  • a public participating hospital, or
  • a public hospital

and is a

  • day admitted patient
  • non-admitted patient, or
  • patient on discharge

This item is not available as a PBS benefit for in-patients of the hospital. The hospital name and provider number must be included on the application form.

Patient eligibility

Patients must meet the relevant criteria in the restrictions and be eligible for the PBS.

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing ivacaftor.

Applications

Patients must be assessed through a cystic fibrosis clinic or centre which is under the control of specialist respiratory physicians with experience and expertise in the management of cystic fibrosis. If attendance at the unit is not possible because of geographical isolation, management (including prescribing) may be in consultation with such a unit. The patients must be registered with Australian Cystic Fibrosis Database Registry.

Initial treatment

Make all initial applications for authority approval to prescribe ivacaftor for the treatment of cystic fibrosis in writing and:

All applications must include a completed:

Initial grandfather treatment

For patients aged 2 to 5 years who received non PBS subsidised ivacaftor treatment for cystic fibrosis before 1 May 2017, make all initial grandfather applications in writing and:

All applications must include a completed:

The patient can qualify for PBS subsidised treatment under this restriction once only. For continuing PBS subsidised treatment, a grandfathered patient must qualify under the continuing treatment criteria.

Continuing treatment

Make all continuing applications for authority approval to prescribe ivacaftor for the treatment of cystic fibrosis in writing and:

All applications must include a completed:

Further information

For more information contact us on the Complex Drugs enquiry line.

We’re testing a new website design. Try it out and tell us what you think. Read more about changes to this site.

Page last updated: 1 May 2017

This information was printed Tuesday 22 August 2017 from humanservices.gov.au/health-professionals/enablers/cystic-fibrosis It may not include all of the relevant information on this topic. Please consider any relevant site notices at humanservices.gov.au/siteinformation when using this material.